胸腺肽对于复治涂阳肺结核患者的治疗价值分析

Thymosin in treatment of retreatment smear-positive pulmonary tuberculosis

目的分析探讨胸腺肽治疗复治涂阳肺结核的临床价值。方法自2012年1月1日至2014年6月30日，我院共收治复治涂阳肺结核患者160例，按照随机自愿的原则分为治疗组和对照组，对照组采用常规复治涂阳肺结核治疗方法，治疗组在对照组常规治疗的基础上，采用胸腺肽免疫增强疗法，连续用药4周，比较分析两组痰菌检测结果、临床症状改善情况以及药物不良反应发生状况。结果两组经治疗后，治疗组患者痰菌转阴率为93．4％，显著高于对照组患者痰菌转阴率76．3％，治疗组痰菌平均转阴时间（6．87±2．13）d，显著低于对照组痰菌平均转阴时间（10．76±2．87）d，两组比较差异具有统计学意义（P〈0．05）；治疗组总有效率为90．0％，显著高于对照组总有效率67．5％，两组比较差异具有统计学意义（P〈0．05）。结论胸腺肽联合抗结核药治疗复治涂阳肺结核，疗效显著，且无明显副作用，值得临床推广应用。

Objective To explore the therapeutic value ofthymosin in the treatment ofretreatment smear-positive pulmonary tuberculosis. Methods 160 patients with retreatment smear-positive pulmonary tuberculosis admitted into our hospital from January 1st, 2012 to June 30th, 2014 were voluntarily and randomly divided into a treatment group and a control group. The control group was given conventional chemotherapy. In addition, the treatment group was treated with thymosin. Both groups were continuously treated for 4 weeks. The sputum bacteria detection results, clinical symptoms and adverse drug reactions of the two groups were compared and analyzed. Results The sputum negative rate of the treatment group was 93.4%, which was significantly higher than that of the control group （76.3%）; the time for sputum becoming negative of the treatment group was （6.87＋2.13） d, which was significantly lower than that of the control group [（10.76~2.87）d ]（P〈0.05）; the total effective rate of the treatment group was 90.0%, which was significantly higher than that of the control group （67.5%） （P〈0.05）. Conclusions The therapeutic value of thymosin combined with anti-tuberculosis drug for retreatment smear-positive pulmonary tuberculosis and is an effective option with acceptable side effects is worth being clinically generalized.